Home › NDC Lookup › Ingredients › Labetalol Hydrochloride › 00143-9183-10
Labetalol Hydrochloride 5 mg/mL Injection, Solution — NDC 00143-9183-10 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Labetalol Hydrochloride 5 mg/mL Injection, Solution — NDC 0143-9183-10 (Billing 00143-9183-10)

by Hikma Pharmaceuticals USA Inc. · 10 VIAL in 1 CARTON / 4 mL in 1 VIAL

This is a package of Labetalol Hydrochloride 5 mg/mL Injection, Solution from Hikma Pharmaceuticals USA Inc., marketed since Aug 2025 and currently FDA-listed. It is this product's only package size.

NDC 00143-9183-10
🏷️ FDA NDC (as labeled) 0143-9183-10 billing pads the labeler segment with a zero
Rx only Brand On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

⚠️
Other active recalls for Labetalol Hydrochloride (different manufacturers) — 1 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · May 20, 2024 — Lack of Assurance of Sterility-The potential for incomplete crimp seals. (Pfizer Inc.) · FDA recall D-0565-2024
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 0143-9183-10
Product NDC 0143-9183
11-digit billing NDC 00143918310
NCPDP billing unit ML — per mL (volume)
RxCUI 2477889, 2479564, 2479566, 2479567
UNII 1GEV3BAW9J
Application # NDA213330
SPL Set ID 99a715a0-4579-410c-b102-7ef6fab8db55
Established class (EPC) beta-Adrenergic Blocker
Mechanism of action Adrenergic beta-Antagonists
DEA schedule Non-controlled
Marketing category NDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2025-08-28
Route INTRAVENOUS
Dosage form INJECTION, SOLUTION
Substance LABETALOL HYDROCHLORIDE

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GCN Seq No 005097
GCN 18990
HICL code 002095
Ingredient (HICL) Labetalol Hcl
HIC1 code J
Therapeutic class — broad (HIC1) Autonomic Nervous System
HIC2 code J7
Therapeutic class — intermediate (HIC2) Antiadrenergics
HIC3 code J7A
Therapeutic class — specific (HIC3) Alpha/Beta-Adrenergic Blocking Agents
AHFS code 12:16.04.12
AHFS class Selective Alpha-1-Adrenergic Block.agent
FDB label name LABETALOL HCL 20 MG/4 ML VIAL
FDB brand name Labetalol Hcl
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 005097
  • GCN: 18990
  • HICL (First Databank): 002095
  • AHFS class code: 12:16.04.12
  • RxCUI (RxNorm): 2477889
Why two NDCs? The FDA registers this code as 0143-9183-10 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00143-9183-10. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the beta-Adrenergic Blocker class.

Pharmacologic class beta-Adrenergic Blocker
Drug family (ATC) Alpha and beta blocking agents
How it works Adrenergic beta-Antagonists
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name LABETALOL HCL 20 MG/4 ML VIAL Ingredient Labetalol Hcl
📗 Our plain-language guide HelloPharmacist
  • Labetalol lowers blood pressure. The tablets are used for high blood pressure, and the IV form is used in the hospital for severe high blood pressure. Keeping blood pressure down r...
  • Take them by mouth, usually twice a day, as your prescriber directs. Food increases how much of the drug your body absorbs, so try to be consistent about taking it with or without...
  • Dizziness, nausea, tiredness and headache are the most common, and they often fade early in treatment. Standing up slowly helps with lightheadedness. Call your doctor if you get it...
  • Please don't stop suddenly. Stopping a beta blocker abruptly can worsen chest pain and, in some cases, lead to a heart attack. If you need to stop, your prescriber will lower the d...
📖 Read our full Labetalol guide →

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
1
Nutrient depletion considerations

Labetalol may be associated with lower levels of 1 nutrient — worth a chat with your pharmacist, not a cause for alarm.

🧪 Full Labetalol nutrient depletion report →
An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
Medicare Part B allowsASP · J1921 $0.906 / J1921 unit —
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Billing & reimbursement

FDA NDC (as labeled)0143-9183-10
11-digit billing NDC00143-9183-10
Format4-4-2 as registered → padded to 5-4-2 for billing (zero added to the labeler segment)
HCPCS J-codeJ1921
DescriptorINJECTION, LABETALOL HYDROCHLORIDE (HIKMA), NOT THERAPEUTICALLY EQUIVALENT TO J1920, 5 MG
Billing units / pkg1 units
How the units are derivedThis package is 4 ML; the HCPCS unit is 5 MG, so one package = 1 billing unit.
Crosswalk sourcePDAC NDC-HCPCS crosswalk (DME MAC / DMEPOS)
Where does this data come from?
The HCPCS J-code crosswalk comes from the CMS ASP NDC-HCPCS crosswalk and the DMEPDAC (DME MAC) NDC-HCPCS crosswalk — free public CMS data. Billing units are derived from the code’s descriptor and the package amount.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
00143-9183-10 You're viewing this Main listing 10 VIAL in 1 CARTON / 4 mL in 1 VIAL 2025-08-28 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
labetalol hydrochloride 5 mg/mL 25021-0317-20 Sagent 1 vial $0.185 AP Availability likely —
Labetalol Hydrochloride 5 mg/mL 72603-0146-01 NorthStar 1 vial $0.185 AP Availability likely —
Labetalol Hydrochloride 5 mg/mL 00143-9622-01 Hikma 1 vial $0.185 AP Availability likely —
Labetalol Hydrochloride 5 mg/mL 36000-0322-02 Baxter 1 vial $0.185 AP Availability likely —
Labetalol Hydrochloride 5 mg/mL 65145-0124-01 Caplin 1 vial $0.185 AP Availability likely —
Labetalol Hydrochloride 5 mg/mL 72572-0350-01 Civica, 1 vial $0.185 AP Availability likely —
Labetalol Hydrochloride 5 mg/mL 00143-9320-01 Hikma 1 vial $0.185 AP Availability likely —
Labetalol Hydrochloride 5 mg/mL 72266-0102-01 Fosun 1 vial $0.185 AP Availability likely —
Labetalol Hydrochloride 5 mg/mLthis 00143-9183-10 Hikma 10 vials — — FDA listed —
Labetalol Hydrochloride 5 mg/mL 36000-0320-10 Baxter 10 vials — AP FDA listed —
Labetalol Hydrochloride 5 mg/mL 00409-2339-34 Hospira, 1 cartridge — AP FDA listed —
Labetalol Hydrochloride 5 mg/mL 00409-2267-20 Hospira, 1 vial — AP Discontinued —
Labetalol Hydrochloride 5 mg/mL 72266-0103-01 Fosun 1 vial — AP FDA listed —
Labetalol Hydrochloride 5 mg/mL 36000-0324-02 Baxter 1 vial — AP FDA listed —
Labetalol Hydrochloride 5 mg/mL 55154-4747-05 Cardinal 5 cartridges — AP FDA listed —
Labetalol Hydrochloride 5 mg/mL 68083-0111-01 Gland 10 vials — AP FDA listed —
Labetalol Hydrochloride 5 mg/mL 00409-0125-25 Hospira, 25 vials — AP FDA listed —
Labetalol Hydrochloride 5 mg/mL 00143-9623-01 Hikma 1 vial — AP FDA listed —
Labetalol Hydrochloride 5 mg/mL 65145-0125-01 Caplin 1 vial — AP FDA listed —
Labetalol Hydrochloride 5 mg/mL 70121-2428-03 Amneal 1 syringe — AP FDA listed —
Labetalol Hydrochloride 5 mg/mL 83270-0178-01 Onesource 1 vial — — FDA listed —
Labetalol Hydrochloride 5 mg/mL 83270-0179-01 Onesource 1 vial — — FDA listed —
About this product: this is the brand-name version. FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2025
On the market since
Aug 2025
📍
2026
Currently FDA-listed
1 year listed
🔓
·
Generic versions listed
see equivalents
✅Generic appears available

FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • 45 mg / 1 mL UNII 5SL0G7R0OK
    A simple sugar made from corn or other plants, used in medicines as a filler and sweetener. It helps create the right texture and taste in tablets, powders, and liquid formulations.
  • UNII 2968PHW8QP
    A weak organic acid derived from citrus fruits or made through fermentation. It works as a buffer to control pH, a preservative to extend shelf life, and a flavoring agent in medications.
  • 0.1 mg / 1 mL UNII 7FLD91C86K
    Edetate disodium is a chemical compound that binds and removes certain metal ions. In medicines, it acts as a preservative and stabilizer by preventing metals like calcium from interfering with the product's shelf life and consistency.
  • UNII 55X04QC32I
    A strong alkaline chemical used to adjust and maintain the pH balance of liquid medicines. It helps keep the medicine stable and ensures it stays effective during storage.

4 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerHikma Pharmaceuticals USA Inc.
Application holderHIKMA PHARMACEUTICALS USA INC
FDA applicationNDA213330 (NDA)
Labeler code00143
First marketedAug 2025
Product typeHuman Prescription Drug
Portfolio726 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Very long sections are excerpted here and marked; the full text is on DailyMed (linked in the sources below). Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration 💊 Dosage Forms and Strengths ⛔ Contraindications ⚠️ Warnings and Cautions 🤒 Adverse Reactions 🔄 Drug Interactions 👥 Use in Specific Populations 🤰 Pregnancy 🧒 Pediatric Use 🧓 Geriatric Use 🆘 Overdosage 🧬 Clinical Pharmacology 🧬 Mechanism of Action 📦 How Supplied / Storage and Handling 📦 Storage and Handling 📋 Description 💬 Information for Patients 🧬 Pharmacodynamics 🧪 Nonclinical Toxicology 📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 38 words ▾

1 INDICATIONS AND USAGE Labetalol HCl Injection is indicated in severe hypertension, to lower blood pressure. Labetalol Hydrochloride (HCl) is a beta-adrenergic blocker. Labetalol HCl injection is indicated in severe hypertension, to lower blood pressure. ( 1 )

⏱️ Dosage and Administration ~2 min read ▾

2 DOSAGE AND ADMINISTRATION Administer Labetalol Hydrochloride in Sodium Chloride Injection or Dextrose Injection as a slow continuous intravenous infusion at a rate of 2 mL/min (2 mg/min). ( 2.2 ) Alternatively, administer Labetalol Hydrochloride Injection in a prefilled syringe or vial at 0.25 mg/kg (up to a maximum of 20 mg) intravenously over 2 minutes. Additional injections of 40 mg or 80 mg can be given at 10-minute intervals. ( 2.2 )

2.1General Information Inspect parenteral drug products for particulate matter and discoloration prior to administration, whenever solution and container permit. Labetalol HCl in Sodium Chloride Injection and Labetalol HCl in Dextrose Injection: Labetalol HCl in Sodium Chloride Injection and Labetalol HCl in Dextrose Injection are ready-to-use solutions and do not require further dilution. Check for leaks by squeezing the bag firmly.

If leaks are found, discard solution, as sterility may be impaired. Do not add any additional medications to the bag. Once infusion has started, discard any remaining at 24 hours.

Labetalol HCl Injection in a prefilled syringe or vial: Labetalol HCl Injection, USP, in a prefilled syringe or vial are ready-to-use solutions that do not require further dilution. The prefilled syringe and vial are intended for single dose. Discard any unused portion.

2.2Recommended Dosage Labetalol HCI can be administered by slow continuous intravenous infusion or repeated intravenous injection. Once supine diastolic blood pressure has begun to rise, transition to oral labetalol HCl. Slow Continuous Intravenous Infusion: Initiate at 2 mg/minute.

Monitor blood pressure and adjust the dosage and duration of infusion accordingly. Repeated Intravenous Injection: Administer 0.25 mg/kg up to 20 mg over 2 minutes. Administer 20 mg to 80 mg over 2 minutes at 10-minute intervals until a desired supine blood pressure is achieved.

The maximum effect usually occurs within 5 minutes of each injection. The safety of doses above 300 mg has not been established.

2.3Instructions for Use of Labetalol HCl Injection Prefilled Syringe CAUTION: Glass syringes may malfunction, break or clog when connected to some Needleless Luer Access Devices (NLADs) and needles. The external collar must remain attached to the syringe (See Figure 1) . Spontaneous disconnection of this glass syringe from needles and NLADs with leakage of drug product may occur.

Assure that the needle or NLAD is securely attached before beginning the injection. Inspect the glass syringe-needle or glass syringe –NLAD connection before and during drug administration. Figure 1 1.

Push plunger rod slightly to break the stopper loose while tip cap is still on. 2. Remove tip cap by twisting it off.

(See Figure 2) Figure 2 3. Connect the syringe to an appropriate injection connection. 4.

Depress plunger rod to deliver the required dose. Figure 1 figure 2

💊 Dosage Forms and Strengths 192 words ▾

3 DOSAGE FORMS AND STRENGTHS Labetalol HCl in Sodium Chloride Injection is a clear, colorless to pale yellow solution available as: 100 mg/100 mL (1 mg/mL) in a single-dose bag 200 mg/200 mL (1 mg/mL) in a single-dose bag 300 mg/300 mL (1 mg/mL) in a single-dose bag Labetalol HCl in Dextrose Injection is a clear, colorless to pale yellow solution available as: 200 mg/200 mL (1 mg/mL) in a single-dose bag Labetalol HCl Injection is a clear, colorless to pale yellow solution available as: 10 mg/2 mL (5 mg/mL) in a single-dose prefilled syringe 20 mg/4 mL (5 mg/mL) in a single-dose vial Labetalol HCl Injection solution: 100 mg/100 mL (1 mg/mL) in sodium chloride in a single-dose bag ( 3 ) 200 mg/200 mL (1 mg/mL) in sodium chloride in a single-dose bag ( 3 ) 300 mg/300 mL (1 mg/mL) in sodium chloride in a single-dose bag ( 3 ) 200 mg/200 mL (1 mg/mL) in dextrose in a single-dose bag ( 3 ) 10 mg/2 mL (5 mg/mL) in a single-dose prefilled syringe ( 3 ) 20 mg/4 mL (5 mg/mL) in a single-dose vial ( 3 )

⛔ Contraindications 68 words ▾

4 CONTRAINDICATIONS Labetalol Hydrochloride Injection is contraindicated in patients with: Bronchial asthma or obstructive airway disease. Severe sinus bradycardia: Heart block greater than first degree. Cardiogenic shock.

IV administration of non-dihydropyridine calcium-channel antagonists (e.g., verapamil) Hypersensitivity reactions, including anaphylaxis, to labetalol Bronchial asthma ( 4 ) Overt cardiac failure ( 4 ) Greater-than-first-degree heart block ( 4 ) Cardiogenic shock ( 4 ) Severe bradycardia ( 4 )

⚠️ Warnings and Cautions ~3 min read ▾

5 WARNINGS AND PRECAUTIONS Exacerbation of heart failure: Avoid use. ( 5.3 ) Acute exacerbation of coronary artery disease upon cessation of therapy: Do not abruptly discontinue. ( 5.4 ) Non-allergic bronchospasm (e.g., chronic bronchitis and emphysema): Avoid since it has not been studied.

( 5.5 ) Diabetes: May mask symptoms of hypoglycemia and alter glucose levels; monitor ( 5.6 ) Exacerbation of pheochromocytoma: Paradoxical increases in blood pressure may occur. ( 5.7 ) Severe hepatocellular injury: Discontinue permanently for liver injury or jaundice ( 5.8 )

5.1Hypotension Symptomatic postural hypotension (incidence, 58%) is likely to occur if patients are tilted or allowed to assume the upright position within 3 hours of receiving labetalol HCl injection. Before permitting any ambulation, establish patient’s ability to tolerate an upright position and observe the patient at the time of first ambulation.

5.2Bradycardia Bradycardia, including sinus pause, heart block, severe bradycardia, and cardiac arrest have occurred with the use of beta blockers. Monitor heart rate and rhythm in patients receiving labetalol hydrochloride injection.

5.3Cardiac Failure Sympathetic stimulation is a vital component supporting circulatory function in congestive heart failure. Beta-blockade carries a potential hazard of further depressing myocardial contractility and precipitating more severe failure. Avoid labetalol HCl injection in patients with overt congestive heart failure. If patients develop signs or symptoms of heart failure during administration, discontinue labetalol and treat appropriately.

5.4Ischemic Heart Disease Abrupt cessation of therapy with beta blocking agents in patients with coronary artery disease, can cause exacerbations of angina pectoris and, in some cases, myocardial infarction has been reported. Therefore, even in the absence of overt angina pectoris, after the discontinuation of labetalol HCl injection observe patients for development or worsening of angina. If patient experiences angina or angina markedly worsens or if acute coronary insufficiency develops, promptly reinstitute labetalol HCl injection and manage as unstable angina.

5.5Reactive Airway Disease and Nonallergic Bronchospasm Patients with reactive airways disease should, in general, not receive beta blockers. Labetalol HCl at the usual intravenous therapeutic doses has not been studied in patients with nonallergic bronchospastic disease. In the event of bronchospasm, stop the infusion immediately, and treat as appropriate.

5.6Hypoglycemia Beta-blockers may prevent early warning signs of hypoglycemia, such as tachycardia, and increase the risk for severe or prolonged hypoglycemia at any time during treatment, especially in patients with diabetes mellitus or children and patients who are fasting (i.e., surgery, not eating regularly, or are vomiting). If severe hypoglycemia occurs, patients should be instructed to see medical treatment.

5.7Use in Patients with Pheochromocytoma Intravenous labetalol has been shown to lower blood pressure and relieve symptoms in patients with pheochromocytoma; higher than usual doses may be required. However, paradoxical hypertensive responses have been reported in a few patients with this tumor; therefore, monitor blood pressure when administering intravenous labetalol HCl to patients with pheochromocytoma.

5.8Hepatic Injury Severe hepatocellular injury occurs rarely with labetalol therapy. The hepatic injury is usually reversible, but hepatic necrosis and death have been reported. If the patient develops signs or symptoms of liver injury, institute appropriate treatment and investigate the probable cause. Do not restart labetalol in patients without another explanation for the observed liver injury.

5.9Use in Patients at Risk of Severe Acute Hypersensitivity Reactions Patients at risk of anaphylactic reactions may be more reactive to allergen exposure (accidental, diagnostic, or therapeutic). Patients using bet… [Excerpted — this section continues on DailyMed.]

🤒 Adverse Reactions ~2 min read ▾

6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Hypotension [see Warnings and Precautions (5.1) ] Bradycardia [see Warnings and Precautions (5.2) ] Depression of myocardial contractility in patients with overt congestive heart failure [see Warnings and Precautions (5.3) ] Aggravation of angina [see Warnings and Precautions (5.4) ] Significant decline in cardiac output following coronary bypass [see Warnings and Precautions (5.3) ] Bronchospasm in patients with reactive airway disease [see Warnings and Precautions (5.5) ] Paradoxical hypertensive responses in patients with pheochromocytoma [see Warnings and Precautions (5.7) ] Hepatic injury [see Warnings and Precautions (5.8) ] Acute hypersensitivity reaction [see Warnings and Precautions (5.9) ] Most common adverse events: Symptomatic postural hypotension.

( 6 ) Nausea13%, dizziness 9% ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Hikma Pharmaceuticals USA Inc. at 1-877-845-0689, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. For product Inquiry call 1-877-845-0689.

6.1Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Most adverse effects have been mild and transient and, in controlled trials involving 92 patients, did not require labetalol withdrawal. Symptomatic postural hypotension (incidence, 58%) is likely to occur if patients are tilted or allowed to assume the upright position within 3 hours of receiving labetalol HCl.

Moderate hypotension occurred in 1 of 100 patients while supine. Increased sweating was noted in 4 of 100 patients, and flushing occurred in 1 of 100 patients. The following also were reported with labetalol HCl with the incidence as noted: Central and Peripheral Nervous Systems Dizziness in 9% Paresthesia, most frequently described as tingling of the scalp/skin in 7% Gastrointestinal System Nausea in 13% Vomiting in 4% Metabolic Disorders Transient increases in blood urea nitrogen and serum creatinine levels occurred in 8%; these were associated with drops in blood pressure, generally in patients with prior renal insufficiency.

Respiratory System Bronchospasm In addition, a number of other less common adverse events have been reported: Cardiovascular: Hypotension, and rarely, syncope, bradycardia, heart block. Liver and Biliary System Hepatic necrosis, hepatitis, cholestatic jaundice, elevated liver function tests. Hypersensitivity Rare reports of hypersensitivity (e.g., rash, urticaria, pruritus, angioedema, dyspnea) and anaphylactoid reactions.

The oculomucocutaneous syndrome associated with the beta blocker practolol has not been reported with labetalol HCl during investigational use and extensive foreign marketing experience. Clinical Laboratory Tests Among patients dosed with labetalol tablets, there have been reversible increases of serum transaminases in 4% of patients tested and, more rarely, reversible increases in blood urea.

🔄 Drug Interactions ~2 min read ▾

7 DRUG INTERACTIONS Beta blockers antagonize the bronchodilator effect of beta-receptor agonists. ( 7.1 ) Increase hypotension may occur with halothane anesthesia. ( 7.2 ) Nitroglycerin may result in additional hypotensive effects. ( 7.3 )

7.1Bronchodilators Labetalol HCl antagonizes the bronchodilatory effect of beta-receptor agonist drugs; therefore, labetalol HCl is contraindicated in patients with bronchial asthma [see Contraindications (4) ] .

7.2Anesthesia Synergism has been shown between halothane anesthesia and intravenously administered labetalol. During controlled hypotensive anesthesia using labetalol in association with halothane, high concentrations (3% or above) of halothane should not be used because the degree of hypotension will be increased and because of the possibility of a large reduction in cardiac output and an increase in central venous pressure.

7.3Nitroglycerin Coadministration of labetalol HCl and nitroglycerin will have an additive effect in lowering blood pressure. Additionally, labetalol HCl blunts the reflex tachycardia produced by nitroglycerin. If labetalol is used in patients with angina pectoris on nitroglycerin, monitor patients’ blood pressure and adjust labetalol HCl injection dose as needed. In these patients, avoid initiating labetalol HCl tablets.

7.4Calcium Channel Blockers Coadministration of labetalol HCl with non-dihydropyrindine calcium-channel antagonists (e.g., verapamil) is contraindicated [see Contraindications (4) ]. Avoid the use of labetalol in patients receiving calcium-channel antagonists.

7.5Drug/Laboratory Test Interactions The presence of labetalol metabolites in the urine may result in falsely elevated levels of urinary catecholamines, metanephrine, normetanephrine, and vanillylmandelic acid (VMA) when measured by fluorimetric or photometric methods. In screening patients suspected of having a pheochromocytoma and being treated with labetalol, a specific method, such as a high-performance liquid chromatographic assay with solid phase extraction should be employed in determining levels of catecholamines.

Labetalol has also been reported to produce a false-positive test for amphetamine when screening urine for the presence of drugs using the commercially available assay methods. When patients being treated with labetalol have a positive urine test for amphetamine using these techniques, confirm using more specific methods, such as a gas chromatographic-mass spectrometer technique.

👥 Use in Specific Populations ~3 min read ▾

8 USE IN SPECIFIC POPULATIONS

8.1Pregnancy Risk Summary The extensive experience with use of labetalol in pregnant women, based on published interventional and observational studies, has not identified a drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes (see Data). Untreated hypertension during pregnancy can lead to serious adverse outcomes for the mother and the fetus (see Clinical Considerations) . In animal reproduction studies, oral administration of labetalol to pregnant rats and rabbits during organogenesis at doses up to approximately six and four times the maximum recommended human dose (MRHD), respectively, resulted in no fetal malformations; however, increased fetal resorptions were seen in both species at doses approximating the MRHD (see Data) .

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. The background risk of major birth defects and miscarriage for the indicated population is unknown. Clinical Considerations Disease-Associated Maternal and/or Embryo/Fetal Risk Hypertension in pregnancy increases the maternal risk for pre-eclampsia, gestational diabetes, premature delivery, and delivery complications (e.g., need for cesarean section, and post-partum hemorrhage).

Hypertension increases the fetal risk for intrauterine growth restriction and intrauterine death. Pregnant women with hypertension should be carefully monitored and managed accordingly. Fetal/Neonatal Adverse Reactions Labetalol crosses the placenta.

Neonates born to mothers who are receiving labetalol during pregnancy, may be at risk for hypotension, bradycardia, hypoglycemia, and respiratory depression. Neonates should be monitored for symptoms of hypotension, bradycardia, hypoglycemia and respiratory depression and manage accordingly. Data Human Data Data from published interventional and observational studies did not demonstrate an association between major congenital malformations and the use of labetalol in pregnancy, however, most studies reported the maternal use of intravenous labetalol occurring after 20 weeks gestation.

The published literature has reported inconsistent findings of intrauterine growth retardation, preterm birth and perinatal mortality with maternal use of labetalol during pregnancy; however, these studies have methodological limitations hindering interpretation. These studies cannot definitively establish the absence of risk during pregnancy. Animal Data Teratogenic studies were performed with labetalol in rats and rabbits at oral doses up to approximately six and four times the maximum recommended human dose (MRHD), respectively.

No reproducible evidence of fetal malformations was observed. Increased fetal resorptions were seen in both species at doses approximating the MRHD. A teratology study performed with labetalol in rabbits at intravenous doses up to 1.7 times the MRHD revealed no evidence of drug-related harm to the fetus.

Oral administration of labetalol to rats during late gestation through weaning at doses of two to four times the MRHD caused a decrease in neonatal survival.

8.2Lactation Risk Summary Available published data report the presence of labetalol in human milk at low levels. There are no data on the effects on the breastfed infant and on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for labetalol and any potential adverse effects on the breastfed infant from labetalol or from the underlying maternal condition.

8.3Females and Males of Reproductive Potential Infertility Based on the published literature, beta blockers, including labetalol, may cause erectile dysfunction and inhibit sperm motility.

8.4Pediatric Use Safety and effectiveness in pediatric patients have not been established.

8.5Geriatric Use Some pharmacokinetic studies indicate th… [Excerpted — this section continues on DailyMed.]

🤰 Pregnancy ~2 min read ▾

8.1Pregnancy Risk Summary The extensive experience with use of labetalol in pregnant women, based on published interventional and observational studies, has not identified a drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes (see Data). Untreated hypertension during pregnancy can lead to serious adverse outcomes for the mother and the fetus (see Clinical Considerations) . In animal reproduction studies, oral administration of labetalol to pregnant rats and rabbits during organogenesis at doses up to approximately six and four times the maximum recommended human dose (MRHD), respectively, resulted in no fetal malformations; however, increased fetal resorptions were seen in both species at doses approximating the MRHD (see Data) .

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. The background risk of major birth defects and miscarriage for the indicated population is unknown. Clinical Considerations Disease-Associated Maternal and/or Embryo/Fetal Risk Hypertension in pregnancy increases the maternal risk for pre-eclampsia, gestational diabetes, premature delivery, and delivery complications (e.g., need for cesarean section, and post-partum hemorrhage).

Hypertension increases the fetal risk for intrauterine growth restriction and intrauterine death. Pregnant women with hypertension should be carefully monitored and managed accordingly. Fetal/Neonatal Adverse Reactions Labetalol crosses the placenta.

Neonates born to mothers who are receiving labetalol during pregnancy, may be at risk for hypotension, bradycardia, hypoglycemia, and respiratory depression. Neonates should be monitored for symptoms of hypotension, bradycardia, hypoglycemia and respiratory depression and manage accordingly. Data Human Data Data from published interventional and observational studies did not demonstrate an association between major congenital malformations and the use of labetalol in pregnancy, however, most studies reported the maternal use of intravenous labetalol occurring after 20 weeks gestation.

The published literature has reported inconsistent findings of intrauterine growth retardation, preterm birth and perinatal mortality with maternal use of labetalol during pregnancy; however, these studies have methodological limitations hindering interpretation. These studies cannot definitively establish the absence of risk during pregnancy. Animal Data Teratogenic studies were performed with labetalol in rats and rabbits at oral doses up to approximately six and four times the maximum recommended human dose (MRHD), respectively.

No reproducible evidence of fetal malformations was observed. Increased fetal resorptions were seen in both species at doses approximating the MRHD. A teratology study performed with labetalol in rabbits at intravenous doses up to 1.7 times the MRHD revealed no evidence of drug-related harm to the fetus.

Oral administration of labetalol to rats during late gestation through weaning at doses of two to four times the MRHD caused a decrease in neonatal survival.

🧒 Pediatric Use 13 words ▾

8.4Pediatric Use Safety and effectiveness in pediatric patients have not been established.

🧓 Geriatric Use 82 words ▾

8.5Geriatric Use Some pharmacokinetic studies indicate that the elimination of labetalol is reduced in elderly patients [see Clinical Pharmacology (12.3) ] . Geriatric patients treated with labetalol could initiate therapy at the currently recommended dose of 2 mg/minute by continuous intravenous infusion; however, lower maintenance dosages are generally required for elderly patients than nonelderly patients. Monitor blood pressure and adjust the dosage and duration of infusion accordingly until the desired response is obtained [see Dosage and Administration (2 ) ] .

🆘 Overdosage 131 words ▾

10 OVERDOSAGE

10.1Signs and Symptoms of Overdose Overdosage with labetalol HCl causes excessive hypotension that is posture sensitive and, sometimes, excessive bradycardia. Patients should be placed supine and their legs raised if necessary, to improve the blood supply to the brain. Treat symptoms of overdose with standard supportive care.

If overdosage with labetalol HCl follows oral ingestion, gastric lavage or pharmacologically induced emesis (using syrup of ipecac) may be useful for removal of the drug shortly after ingestion. Neither hemodialysis nor peritoneal dialysis removes a significant amount of labetalol from the general circulation (<1%). The oral LD 50 value of labetalol HCl in the mouse is approximately 600 mg/kg and in the rat is greater than 2 g/kg.

The intravenous LD 50 in these species is 50 to 60 mg/kg.

🧬 Clinical Pharmacology ~2 min read ▾

12 CLINICAL PHARMACOLOGY

12.1Mechanism of Action Labetalol has both competitive alpha1-adrenergic blocking and competitive beta-adrenergic blocking activity. In man, the ratio of alpha- to beta-blockade has been estimated to be approximately 1:7 following intravenous administration. Beta 2 -agonist activity has been demonstrated in animals with minimal beta 1 -agonist activity detected.

12.2Pharmacodynamics In a clinical pharmacologic study in severe hypertensives, an initial 0.25 mg/kg injection of labetalol HCl administered to patients in the supine position decreased blood pressure by an average of 11/7 mmHg. Additional injections of 0.5 mg/kg at 15-minute intervals up to a total cumulative dose of 1.75 mg/kg of labetalol HCl caused further dose-related decreases in blood pressure. Some patients required cumulative doses of up to 3.25 mg/kg.

The maximal effect of each dose level occurred within 5 minutes. Following discontinuation of intravenous treatment with labetalol HCl, the blood pressure rose gradually and progressively, approaching pretreatment baseline values within an average of 16 to 18 hours in the majority of patients. Similar results were obtained in the treatment of patients with severe hypertension who required urgent blood pressure reduction with an initial dose of 20 mg (which corresponds to 0.25 mg/kg for an 80 kg patient) followed by additional doses of either 40 mg or 80 mg at 10 minute intervals to achieve the desired effect, or up to a cumulative dose of 300 mg.

Labetalol HCl administered as a continuous intravenous infusion, with a mean dose of 136 mg (27 mg to 300 mg) over a period of 2 to 3 hours (mean of 2 hours and 39 minutes), lowered the blood pressure by an average of 60/35 mmHg.

12.3Pharmacokinetics Distribution Labetalol has been shown to cross the placental barrier in humans. Only negligible amounts of the drug crossed the blood-brain barrier in animal studies. Labetalol is approximately 50% protein bound.

Neither hemodialysis nor peritoneal dialysis removes a significant amount of labetalol from the systemic circulation (<1%). Elimination Following intravenous infusion of labetalol, the elimination half-life is about 5.5 hours and the total body clearance is approximately 33 mL/min/kg. Steady-state plasma levels of labetalol during repetitive dosing are reached following 22 to 28 hours of continuous infusion.

Metabolism The metabolism of labetalol is mainly through conjugation to glucuronide metabolites. Excretion Approximately 55% to 60% of a dose appears in the urine as conjugates or unchanged labetalol within the first 24 hours of dosing. The metabolites are present in plasma and are excreted in the urine and, via the bile, into the feces.

Specific Populations Patients with Renal or Hepatic Impairment In patients with decreased hepatic or renal function, the elimination half-life of labetalol is not altered. Geriatric Patients Some pharmacokinetic studies indicate that the elimination of labetalol is reduced in elderly patients.

🧬 Mechanism of Action 49 words ▾

12.1Mechanism of Action Labetalol has both competitive alpha1-adrenergic blocking and competitive beta-adrenergic blocking activity. In man, the ratio of alpha- to beta-blockade has been estimated to be approximately 1:7 following intravenous administration. Beta 2 -agonist activity has been demonstrated in animals with minimal beta 1 -agonist activity detected.

📦 How Supplied / Storage and Handling ~2 min read ▾

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1How Supplied Labetalol HCl in Sodium Chloride Injection and Labetalol HCl in Dextrose Injection are preservative-free, clear, colorless to pale yellow sterile solutions that are available in a single-dose single-port bag with an aluminum overwrap. The container closure is not made with natural rubber latex. It is available in the following presentations: Product Strength Package NDC Number Labetalol HCl in Sodium Chloride Injection 100 mg/100 mL (1 mg/mL) preservative-free 1 single-dose bag 0143-9363-01 Box of 10 bags 0143-9363-10 Labetalol HCl in Sodium Chloride Injection 200 mg/200 mL (1 mg/mL) preservative-free 1 single-dose bag 0143-9364-01 Box of 10 bags 0143-9364-10 Labetalol HCl in Sodium Chloride Injection 300 mg/300 mL (1 mg/mL) preservative-free 1 single-dose bag 0143-9365-01 Box of 10 bags 0143-9365-10 Labetalol HCl in Dextrose Injection 200 mg/200 mL (1 mg/mL) preservative-free 1 single-dose bag 0143-9366-01 Box of 10 bags 0143-9366-10 Labetalol Hydrochloride Injection, USP is a preservative-free, clear, colorless to pale yellow sterile solution that is available in a single-dose prefilled syringe or vial.

It is available in the following presentations: Product Strength Package NDC Number Labetalol Hydrochloride Injection, USP 10 mg/2 mL (5 mg/mL) preservative-free 1 single-dose prefilled syringe 0641-6252-01 Carton of 10 prefilled syringes 0641-6252-10 Labetalol Hydrochloride Injection, USP 20 mg/4 mL (5 mg/mL) preservative-free 1 single-dose vial 0143-9183-01 Carton of 10 vials 0143-9183-10

16.2Storage Store at 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30° C (59°F to 86° F) [see USP Controlled Room Temperature]. DO NOT FREEZE. PROTECT FROM LIGHT. Labetalol HCl in Sodium Chloride Injection and Labetalol HCl in Dextrose Injection: Do not remove from overwrap until ready to use. Labetalol Hydrochloride Injection, USP, prefilled syringe and vial: Retain in carton until time of use.

16.1How Supplied Labetalol HCl in Sodium Chloride Injection and Labetalol HCl in Dextrose Injection are preservative-free, clear, colorless to pale yellow sterile solutions that are available in a single-dose single-port bag with an aluminum overwrap. The container closure is not made with natural rubber latex. It is available in the following presentations: Product Strength Package NDC Number Labetalol HCl in Sodium Chloride Injection 100 mg/100 mL (1 mg/mL) preservative-free 1 single-dose bag 0143-9363-01 Box of 10 bags 0143-9363-10 Labetalol HCl in Sodium Chloride Injection 200 mg/200 mL (1 mg/mL) preservative-free 1 single-dose bag 0143-9364-01 Box of 10 bags 0143-9364-10 Labetalol HCl in Sodium Chloride Injection 300 mg/300 mL (1 mg/mL) preservative-free 1 single-dose bag 0143-9365-01 Box of 10 bags 0143-9365-10 Labetalol HCl in Dextrose Injection 200 mg/200 mL (1 mg/mL) preservative-free 1 single-dose bag 0143-9366-01 Box of 10 bags 0143-9366-10 Labetalol Hydrochloride Injection, USP is a preservative-free, clear, colorless to pale yellow sterile solution that is available in a single-dose prefilled syringe or vial.

It is available in the following presentations: Product Strength Package NDC Number Labetalol Hydrochloride Injection, USP 10 mg/2 mL (5 mg/mL) preservative-free 1 single-dose prefilled syringe 0641-6252-01 Carton of 10 prefilled syringes 0641-6252-10 Labetalol Hydrochloride Injection, USP 20 mg/4 mL (5 mg/mL) preservative-free 1 single-dose vial 0143-9183-01 Carton of 10 vials 0143-9183-10

📦 Storage and Handling 69 words ▾

16.2Storage Store at 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30° C (59°F to 86° F) [see USP Controlled Room Temperature]. DO NOT FREEZE. PROTECT FROM LIGHT. Labetalol HCl in Sodium Chloride Injection and Labetalol HCl in Dextrose Injection: Do not remove from overwrap until ready to use. Labetalol Hydrochloride Injection, USP, prefilled syringe and vial: Retain in carton until time of use.

📋 Description ~1 min read ▾

11 DESCRIPTION Labetalol HCl in Sodium Chloride Injection, Labetalol HCl in Dextrose Injection and Labetalol Hydrochloride Injection, USP contain labetalol HCl an adrenergic receptor blocking agent that has both selective alpha1-adrenergic and nonselective beta-adrenergic receptor blocking actions. Labetalol hydrochloride (HCl) is a racemate chemically designated as 5-[1-Hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl]-salicylamide monohydrochloride and it has the following structural formula: Labetalol HCl is a white or off-white crystalline powder, soluble in water.

Labetalol HCl has the molecular formula C19H24N2O3•HCl and a molecular weight of 364.87. It has two asymmetric centers and therefore exists as a molecular complex of two diastereoisomeric pairs. Labetalol HCl in Sodium Chloride Injection and Labetalol HCl in Dextrose Injection are two preservative-free, ready- to use formulations of labetalol.

Labetalol HCl in Sodium Chloride Injection and Labetalol HCl in Dextrose Injection are clear, colorless to pale yellow, aqueous, sterile, isotonic solution for intravenous injection. Each milliliter of Labetalol HCl in Sodium Chloride Injection contains 1 mg of labetalol HCl, 7.2 mg sodium chloride, 9 mg of anhydrous dextrose, 0.02 mg of edetate disodium; and citric acid monohydrate and sodium hydroxide, as necessary, to bring the solution into the pH range of 3.5 to 4.5. Each milliliter of Labetalol HCl in Dextrose Injection contains 1 mg of labetalol HCl, 45 mg of anhydrous dextrose, 0.02 mg of edetate disodium; and citric acid monohydrate and sodium hydroxide, as necessary, to bring the solution into the pH range of 3.5 to 4.5.

Labetalol Hydrochloride Injection prefilled syringe and vial are two preservative-free, ready-to use formulations of labetalol. Labetalol Hydrochloride Injection is a clear, colorless to pale yellow, aqueous, sterile, isotonic solution for intravenous injection. Each milliliter of Labetalol Hydrochloride Injection, USP, contains 5 mg of labetalol HCI, 45 mg of anhydrous dextrose, 0.1 mg of edetate disodium, and citric acid monohydrate and sodium hydroxide, as necessary, to bring the solution into the pH range of 3.0 to 4.5. structural formula

💬 Information for Patients 96 words ▾

17 PATIENT COUNSELING INFORMATION Advise patients to remain supine and to proceed gradually in becoming ambulatory during and immediately following infusion (for up to 3 hours) of labetalol HCl injection. Inform patient to notify their healthcare provider if they experience symptoms of hypotension. Advise about the risk of hypoglycemia when Labetalol is given to patients who are fasting or who are vomiting.

Inform patient to notify their healthcare provider if they experience symptoms of hypoglycemia. [ See Warnings and Precautions (5.6) ]. Distributed by Hikma Pharmaceuticals USA Inc. Berkeley Heights, NJ 07922 PIN539-WES/6 Revised: August 2024

🧬 Pharmacodynamics ~1 min read ▾

12.2Pharmacodynamics In a clinical pharmacologic study in severe hypertensives, an initial 0.25 mg/kg injection of labetalol HCl administered to patients in the supine position decreased blood pressure by an average of 11/7 mmHg. Additional injections of 0.5 mg/kg at 15-minute intervals up to a total cumulative dose of 1.75 mg/kg of labetalol HCl caused further dose-related decreases in blood pressure. Some patients required cumulative doses of up to 3.25 mg/kg.

The maximal effect of each dose level occurred within 5 minutes. Following discontinuation of intravenous treatment with labetalol HCl, the blood pressure rose gradually and progressively, approaching pretreatment baseline values within an average of 16 to 18 hours in the majority of patients. Similar results were obtained in the treatment of patients with severe hypertension who required urgent blood pressure reduction with an initial dose of 20 mg (which corresponds to 0.25 mg/kg for an 80 kg patient) followed by additional doses of either 40 mg or 80 mg at 10 minute intervals to achieve the desired effect, or up to a cumulative dose of 300 mg.

Labetalol HCl administered as a continuous intravenous infusion, with a mean dose of 136 mg (27 mg to 300 mg) over a period of 2 to 3 hours (mean of 2 hours and 39 minutes), lowered the blood pressure by an average of 60/35 mmHg.

🧪 Nonclinical Toxicology 55 words ▾

13 NONCLINICAL TOXICOLOGY

13.1Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term oral dosing studies with labetalol for 18 months in mice and for 2 years in rats showed no evidence of carcinogenesis. Studies with labetalol using dominant lethal assays in rats and mice and exposing microorganisms according to modified Ames tests showed no evidence of mutagenesis.

📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 52 words ▾

13.1Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term oral dosing studies with labetalol for 18 months in mice and for 2 years in rats showed no evidence of carcinogenesis. Studies with labetalol using dominant lethal assays in rats and mice and exposing microorganisms according to modified Ames tests showed no evidence of mutagenesis.

📄 Package Label / Principal Display Panel ~2 min read ▾

PRINCIPAL DI SPLAY PANEL NDC 0143-9363-01 Rx only 100 mL Labetalol Hydrochloride in 0.72% Sodium Chloride Injection 100 mg per 100 mL (1 mg/mL) For Intravenous Infusion Ready to Use Sterile, nonpyrogenic Single-Dose Flexible Container NDC 0143-9363-01 Rx only 100 mL Labetalol Hydrochloride in 0.72% Sodium Chloride Injection 100 mg per 100 mL (1 mg/mL) For Intravenous Infusion Ready to Use Sterile, nonpyrogenic Single-Dose Flexible Container bag 9363 100 mg overwrap

PRINCIPAL DI SPLAY PANEL NDC 0143-9364-01 Rx only 200 mL Labetalol Hydrochloride in 0.72% Sodium Chloride Injection 200 mg per 200 mL (1 mg/mL) For Intravenous Infusion Ready to Use Sterile, nonpyrogenic Single-Dose Flexible Container NDC 0143-9364-01 Rx only 200 mL Labetalol Hydrochloride in 0.72% Sodium Chloride Injection 200 mg per 200 mL (1 mg/mL) For Intravenous Infusion Ready to Use Sterile, nonpyrogenic Single-Dose Flexible Container bag 9364 200 mg overwrap

PRINCIPAL DI SPLAY PANEL NDC 0143-9365-01 Rx only 300 mL Labetalol Hydrochloride in 0.72% Sodium Chloride Injection 300 mg per 300 mL (1 mg/mL) For Intravenous Infusion Ready to Use Sterile, nonpyrogenic Single-Dose Flexible Container NDC 0143-9365-01 Rx only 300 mL Labetalol Hydrochloride in 0.72% Sodium Chloride Injection 300 mg per 300 mL (1 mg/mL) For Intravenous Infusion Ready to Use Sterile, nonpyrogenic Single-Dose Flexible Container bag 9365 300 mg overwrap

PRINCIPAL DI SPLAY PANEL NDC 0143-9366-01 Rx only 200 mL Labetalol Hydrochloride in 5% Dextrose Injection 200 mg per 200 mL (1 mg/mL) For Intravenous Infusion Ready to Use Sterile, nonpyrogenic Single-Dose Flexible Container NDC 0143-9366-01 Rx only 200 mL Labetalol Hydrochloride in 5% Dextrose Injection 200 mg per 200 mL (1 mg/mL) For Intravenous Infusion Ready to Use Sterile, nonpyrogenic Single-Dose Flexible Container bag 9366 200 mg overwrap

PRINCIPAL DISPLAY PANEL NDC 0143- 9183 -01Rx only Labetalol HCI Injection, USP 20 mg per 4 mL (5 mg/mL) For Intravenous Use ONLY Preservative-Free 4 mL Single-Dose Vial Discard unused portion NDC 0143- 9183 -10 Rx only Labetalol HCI Injection, USP 20 mg per 4 mL (5 mg/mL) For Intravenous Use ONLY Preservative-Free 10 X 4 mL Single-Dose Vials Discard unused portion Labetalol 4 mL Vial Label Labetalol 4 mL Carton Label

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

About this NDC listing & data coverage

Finished prescription product
What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) ✓ Available
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk ✓ Available
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Hikma Pharmaceuticals USA Inc.. Listing status can change — the directory data on this page refreshes weekly.
Who lists this product with the FDA?
Hikma Pharmaceuticals USA Inc. is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
Does this product have a billing J-code?
Yes — this NDC cross-references HCPCS code J1921 for medical-claim billing (typically used when a product is administered in a clinical setting rather than dispensed at a retail pharmacy). See the Billing section on this page.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 00143-9182-01 · Hikma 00143-9184-25 · Hikma →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.